Tycel Phillips

Subcutaneous Epcoritamab in Relapsed or Refractory Large B-Cell Lymphoma: Pivotal Results from the Phase 2 EPCORE NHL-1 Trial

Introduction:More tolerable, readily available treatment options are needed for patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) to induce deep, durable responses. ...

Michael Roost Clausen ;

Mariana Sacchi ;

Catherine Thieblemont ;

Martin Hutchings ;

Tycel Phillips ;

Pieternella Lugtenburg ;

Herve Ghesquieres ;

Chan Y. Cheah ;

Young R. Do ;

Tatyana Feldman ;

Robin Gasiorowski ;

Wojciech Jurczak ;

Tae Min Kim ;

David J. Lewis ;

Mariolein van der Poe ;

Michelle L. Poon ;

Thomas Doerr ;

Nurgul Kilavuz ;

David Cunningham ;

Menghui Chen ;

11/04/2022

Videos

FDA Approval of Epcoritamab for Patients With R/R Diffuse Large B-Cell Lymphoma

07/06/2023

Tycel Phillips ;

Tycel Phillips, MD, shares insights into the recent FDA approval of epcoritamab as a treatment for patients with relapsed/refractory DLBCL not otherwise specified, including indolent lymphoma and high-grade B-cell lymphoma.

Tycel Phillips, MD, shares...

07/06/2023

Oncology

Videos

Acalabrutinib Combined With Bendamustine and Rituximab for Patients With Treatment-Naive or Relapsed/Refractory MCL

06/26/2023

Tycel Phillips ;

Tycel Phillips, MD, presented data at the 2023 ASCO annual meeting on the safety and efficacy of acalabrutinib in combination with bendamustine and rituximab among patients with treatment-naive or R/R mantle cell lymphoma.

Tycel Phillips, MD, presented...

06/26/2023

Oncology

Videos

Recent Breakthroughs in Therapies for Patients With Mantle Cell Lymphoma

10/23/2023

Tycel Phillips ;

Tycel Phillips, MD, discusses 2 recent advancements in the treatment landscape of mantle cell lymphoma, including the use of BTK inhibitor pirtobrutinib, and CAR T-cell therapy treatment lisocabtagene maraleucel.

Tycel Phillips, MD, discusses 2...

10/23/2023

Oncology

Videos

Exploring the Efficacy of BTK Inhibitor Glofitamab Among Patients With R/R MCL

10/23/2023

Tycel Phillips ;

Tycel Phillips, MD, reports updated findings from a phase 1/2 trial examining the efficacy and safety of glofitamab, a BTK inhibitor, among patients with heavily pretreated R/R mantle cell lymphoma.

Tycel Phillips, MD, reports...

10/23/2023

Oncology

Conference Coverage

Analyzing Response Rate and Line of Therapy Correlation Among Patients With R/R Follicular Lymphoma

12/10/2023

Tycel Phillips ;

At the 65th ASH Annual Meeting, Tycel Phillips, MD, discusses the relationship between the line of treatment, treatment site, and response rates among patients with follicular lymphoma with a poor prognosis, according to findings from a...

At the 65th ASH Annual Meeting,...

12/10/2023

Oncology